Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy

Bibliography

• LEIBOWITZ H, KRUEGER D, MAUNDER L et al: TheFramingham Eye Study monograph: An ophthalmo-logical and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degenera-tion, and visual acuity in a general population of 2631 adults, 1973-1975. Sun'. Ophthalmol. (1980) 24:335–610.
   PubMedGoogle Scholar
• KLEIN R, KLEIN B, LINTON K: Prevalence of age-relatedmaculopathy. The Beaver Dam Eye Study. Ophthal-mology. (1992) 99:933–943.
   PubMed Web of Science ®Google Scholar
• •A classic study describing the prevalence of AMD.
   Google Scholar
• TIELSCH J, JAVITT J, COLEMAN A, KATZ J, SOMMER A: Theprevalence of blindness and visual impairment among nursing home residents in Baltimore [see comments]. N Eng1J Med. (1995) 332:1205–1209.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP:Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch. Ophthalmol (1993) 111:1189–1199.
   PubMed Web of Science ®Google Scholar
• BRESSLER N, BRESSLER S, FINE S: Age-related maculardegeneration. Sun'. Ophthalmol. (1988) 32:375–413.
   PubMed Web of Science ®Google Scholar
• •A classic review on AMD.
   Google Scholar
• FREUND KB, YANNUZZI LA, SORENSON JA: Age-related macular degeneration and choroidal neovasculariza-don. Am. J. Ophthalmol. (1993) 115:786–791.
   PubMed Web of Science ®Google Scholar
• MOISSEIEV J, ALHALEL A, MASURI R, TREISTER G: Theimpact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch. Ophthalmol. (1995) 113:185–189.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP:Argon laser photocoagulation for senile macular degeneration. Arch. Ophthalmol. (1982) 100:912–923.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP:Argon laser photocoagulation for neovascular maculopathy; Three-year results from randomized clinical trials. Arch. Ophthalmol. (1986) 104:694–701.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for neovascular maculopathy; Five-year results from randomized clinical trials. Arch. Ophthalmol. (1991) 109:1109–1114.
   PubMed Web of Science ®Google Scholar
• YOUNG R: Pathophysiology of age-related macular degeneration. Surv. Ophthalmol (1987) 31:291–306.
   PubMed Web of Science ®Google Scholar
• ••Classic papers supporting the traditional therapy of AMDpathogenesis.
   Google Scholar
• EAGLE RJ: Mechanisms of maculopathy. Ophthalmology (1984) 91:613–25.
   PubMed Web of Science ®Google Scholar
• ••See reference [11] for annotation.
   Google Scholar
• SPRAUL C, GROSSNIKLAUS H: Characteristics of drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Arch. Ophthalmol. (1997) 115:267-273. See reference [11] for annotation.
   Google Scholar
• STEEN B, SEJERSEN S, BERGLIN L, SEREGARD S, KVANTA A: Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest. Ophthalmol. Vis. ScL (1998) 39:2194–2200.
   PubMed Web of Science ®Google Scholar
• FARIS R, APTE S, OLSEN B, IWATA K, MILAM A: Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am. J. Pathol. (1997) 150:323–328.
   PubMed Web of Science ®Google Scholar
• •Studies that suggest a role of TIMP in AMD and CNVM pathogenesis.
   Google Scholar
• KAMEI M, HOLLEYFIELD J: TIMP-3 in Bruch's membrane: change during aging and in age-related macular degeneration. Invest. Ophthalmol. Vis. ScL (1999) 40:2367–2375.
   PubMed Web of Science ®Google Scholar
• •See reference [15] for annotation.
   Google Scholar
• FRIEDMAN E: A hemodynamic model of the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. (1997) 124:677–682.
   PubMed Web of Science ®Google Scholar
• ••An important paper that describes the haemodynamicmodel of AMD pathogenesis.
   Google Scholar
• FRIEDMAN E, KRUPSKY S, LANE A et al.: Ocular blood flow velocity in age-related macular degeneration. Ophthalmology (1995) 102:640–646.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN E: A hemodynamic model of the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. (1997) 124:677–682.
   PubMed Web of Science ®Google Scholar
• ••An important paper that describes the haemodynamicmodel of AMD pathogenesis.
   Google Scholar
• GRUNWALD J, HARIPRASAD S, DUPONT J et al.: Foveolar choroidal blood flow in age-related macular degenera-tion. Invest. Ophthalmol. Vis. ScL (1998) 1998:385–390.
   Google Scholar
• CIULLA T, HARRIS A, CHUNG H et al.: Color Doppler imaging reveals reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am. J. Ophthalmol. (1998) 128:75–80.
   Web of Science ®Google Scholar
• CIULLA T, HARRIS A, DANIS R: Choroidal perfusion defects in age-related macular degeneration (letter). Am. J. Ophthalmol. (1998) 126:153–154.
   PubMedGoogle Scholar
• ROSS R, BAROFSKY J, COHEN G, BABER W, PALAO S, GITTER K: Presumed macular choroidal watershed vascular filling, choroidal neovascularization, and systemic vascular disease in patients with age-related macular degeneration. Am. J. Ophthalmol. (1998) 125:71–80.
   PubMed Web of Science ®Google Scholar
• ALLIKMETS R, SHROYER N, SINGH N et al.: Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 277:1805–1807.
   PubMed Web of Science ®Google Scholar
• •Studies that suggest for and against, respectively, a genetic link between AMD and the Stargardt gene.
   Google Scholar
• STONE E, WEBSTER A, VANDENBURGH K et al.: Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration (letter). Nature Genet. (1998) 20:328–329.
   PubMed Web of Science ®Google Scholar
• •See reference [23] for annotation.
   Google Scholar
• DE LA PAZ M, GUY V, ABOU-DONIA S et al: Analysis of the Stargardt disease gene (ABCR) in age-related macular degeneration. Ophthalmology (1999) 106:1531–1536.
   PubMed Web of Science ®Google Scholar
• •See reference [23] for annotation.
   Google Scholar
• SOUIED E, BENLIAN P, AMOUYEL P et al.: The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am. J. Ophthalmol. (1998) 125:353–359.
   PubMed Web of Science ®Google Scholar
• KLAVER C, KLIFFEN M, VAN DUIJN C et al.: Genetic association of apoliprotein E with age-related macular degeneration. Am. J. Hum. Genet. (1998) 63:200–206.
   Google Scholar
• STONE E, LOTERY A, MUNIER F et al.: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nature Genet. (1999) 22:199–202.
   PubMed Web of Science ®Google Scholar
• WEBER B, VOGT G, WOLZ W, IVES E, EWING C: Sorsby's fundus dystrophy is genetically linked to chromo-some 22q13-qter. Nature Genet. (1994) 7:158–161.
   PubMed Web of Science ®Google Scholar
• WEBER B, VOGT G, PRUETT R, STOHR H, FELBOR U: Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nature Genet. (1994) 4:352–356.
   Google Scholar
• DE LA PAZ MA, PERICAK-VANCE MA, LENNON F, HAINES JL, SEDDON JM: Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. Invest. Ophthalmol Vis. ScL (1997) 38:1060–1065.
   PubMed Web of Science ®Google Scholar
• SOMMER A, TIELSCH J, KATZ J, QUIGLEY H et aL:Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl. J. Med. (1991) 325:1440–1442.
   PubMedGoogle Scholar
• CRUICKSHANKS K, KLEIN R, KLEIN B: Sunlight and age related macular degeneration. The Beaver Dam Eye Study. Arch. Ophthalmol. (1993) 111:514–518.
   PubMed Web of Science ®Google Scholar
• CHRISTEN W, GLYNN R, MANSON J, AJANI U, BURING J: A prospective study of cigarette smoking and risk in age-related macular degeneration in men. JAMA (1996) 276:1147–1151.
   PubMed Web of Science ®Google Scholar
• •Classic studies that strongly support cigaretter smoking as a risk factor for AMD.
   Google Scholar
• SEDDON J, WILLET W, SPEIZER F, HANKINSON S: A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA (1996) 276:1141–1146.
   PubMed Web of Science ®Google Scholar
• •See reference [34] for annotation.
   Google Scholar
• SEDDON J, AJANI U, SPERDUTO R et al.: Dietary carote- noids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA (1994) 272:1413–1420.
   PubMed Web of Science ®Google Scholar
• MARES PERLMAN J, BRADY W, KLEIN R et al. Serum antioxidants and age related macular degeneration in
   Google Scholar
• HYMAN L, LILLIENFELD A, FERRIS F, FINE S: Senile macular degeneration: a case-control study. Am. J. Epidemiol. (1983) 118:213–227.
   PubMed Web of Science ®Google Scholar
• MARES PERLMAN J, BRADY W, KLEIN R, VANDENLAN-GENBERG G, KLEIN BMP: Dietary fat and age related maculopathy [see comments]. Arch. Ophthalmol. (1995) 113:743–748.
   PubMedGoogle Scholar
• MICHAELSON IC: The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans. Ophthalmol. Soc. UK (1948) 68:137–180.
   Google Scholar
• KVANTA A: Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr. Eye Res. (1995) 14:1015–1020.
   PubMed Web of Science ®Google Scholar
• AMIN R, PUKLIN J, FRANK R: Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. (1994) 35:3178–3188.
   PubMed Web of Science ®Google Scholar
• •A study that localises growth factors in CNVM from AMD.
   Google Scholar
• LOPEZ P, SIPPY B, LAMBERT H, THACH A, HINTON D:Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. (1996) 37:855–868.
   PubMed Web of Science ®Google Scholar
• REDDY VM, ZAMORA RL, KAPLAN HJ: Distribution ofgrowth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am. J. Ophthalmol. (1995) 120:291–301.
   PubMed Web of Science ®Google Scholar
• YI X, OGATA N, KOMADA M et al.: Vascular endothelialgrowth factor expression in choroidal neovasculariza-tion in rats. Graefes Arch. Clin. Exp. Ophthalmol. (1997) 235:313–319.
   PubMed Web of Science ®Google Scholar
• OKAMOTO N, TOBE T, HACKETT SF et al: Transgenicmice with increased expression of vascular endothe-lial growth factor in the retina: a new model of intrare-tinal and subretinal neovascularization [see comments]. Am. J. Pathol. (1997) 151:281–291.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, TOLENTINO MJ et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol (1996) 114:66–71.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, PIERCE EA, FOLEY ED et al: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA (1995) 92:10457–10461.
   PubMed Web of Science ®Google Scholar
• SMITH LE, KOPCHICK JJ, CHEN W et al.: Essential role ofgrowth hormone in ischemia-induced retinal neovascularization. Science (1997) 276:1706–1709.
   PubMed Web of Science ®Google Scholar
• DANIS RP, BINGAMAN DP, YANG Y, LADD L: Inhibitionof preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology (1996) 103:2099–2104.
   PubMed Web of Science ®Google Scholar
• D'AMORE P: Mechanisms of endothelial growth control. Am. J. Resp. Cell Mole. Biol. (1992) 6:1–8.
   Google Scholar
• BISCHOFF J: Approaches to studying cell adhesionmolecules in angiogenesis. Trends Cell Bioli (1995) 5:69–74.
   PubMed Web of Science ®Google Scholar
• ANAND-APTE B, PEPPER M, VOEST E et a/.:Inhibition ofangiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Ophthalmol. Vis. Sci. (1997) 38:817–823.
   Google Scholar
• FRIEDLANDER M, THEESFELD C, SUGITA M et al:Involve-ment of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA (1996) 93:9764–9769.
   PubMed Web of Science ®Google Scholar
• BROUTY-BOYE D, ZETTER B: Inhibition of cell motility by interferon. Science (1980) 208:516–518.
   PubMed Web of Science ®Google Scholar
• SIDKY Y, BORDEN E: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. (1987) 47:5151–5161.
   Google Scholar
• WHITE C, SONDHEIMER H, CROUCH E, WILSON H, FAN L:Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a. N Engl. J. Med. (1989) 320:1197–1200.
   PubMed Web of Science ®Google Scholar
• EZEKOWITZ R, MULLIKEN J, FOLKMAN J: Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl. J. Med. (1992) 326:1456–1463.
   PubMed Web of Science ®Google Scholar
• FUNG WE: Interferon alpha 2a for treatment ofage-related macular degeneration. Am. J. Ophthalmol (1991) 112:349–350.
   PubMed Web of Science ®Google Scholar
• ENGLER C, SANDER B, VILLUMSEN J, LUND-ANDERSEN H:Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation. Br. J. Ophthalmol (1994) 78:749–753.
   PubMed Web of Science ®Google Scholar
• CHAN CK, KEMPIN SJ, NOBLE SK, PALMER GA: The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study. Ophthalmology (1994) 101:289–300.
   Google Scholar
• MILLER JW, STINSON WG, FOLKMAN J: Regression ofexperimental iris neovascularization with systemic alpha-interferon. Ophthalmology (1993) 100:9–14.
   PubMed Web of Science ®Google Scholar
• JAAKKOLA A, ANTTILA PM, IMMONEN I: Interferon alpha-2a in the treatment of exudative senile macular degeneration. Acta Ophthalmol. (Copenh). (1994) 72:545–549.
   PubMed Web of Science ®Google Scholar
• THOELEN A, MENOZZI M, HUBER C, MESSMER E: Treatment of choroidal neovascularization in age-related macular degeneration with interferon alpha-2a: a short term, nonrandomized pilot study. Geri. Ophthalmol. (1995) 4:137–143.
   PubMedGoogle Scholar
• THOMAS M, IBANEZ H: Interferon alfa-2a in thetreatment of subfoveal choroidal neovascularization. Am. J. Ophthalmol. (1993) 115:563–568.
   PubMed Web of Science ®Google Scholar
• PHARMACOLOGICAL THERAPY FOR MACULAR DEGENERATION STUDY GROUP: Interferon Alfa-2a is ineffective for patients with choroidal neovasculariza-tion secondary to age-related macular degeneration. Arch. Ophthalmol. (1997) 115:865–872.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, INGBER D: Angiostatic steroids. Ann. Surg. (1987) 206:374–382.
   PubMed Web of Science ®Google Scholar
• Ocular Histoplasmosis. Schlaegel TF (1977) Grune & Stratton, New York.
   Google Scholar
• ISHIBASHI T, MIKI K, SORGENTE N, PATTERSON R, RYAN SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol. (1985) 103:708–711.
   PubMed Web of Science ®Google Scholar
• PENFOLD P, GYORY J, HUNYOR A, BILLSON F: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. NZ J. Ophthalmol. (1995) 23:293–298.
   PubMed Web of Science ®Google Scholar
• CHALLA JK, GILLIES MC, PENFOLD PL, GYORY JF, HUNYOR AB, BILLSON FA: Exudative macular degenera-tion and intravitreal triamcinolone: 18 month follow up. Aust. NZ J. Ophthalmol. (1998) 26:277–281.
   PubMedGoogle Scholar
• CLARK A, MELLON J, LI X eta].: Inhibition of intraocular tumor growth by topical application of the antiangio-genic steroid anecortave acetate. Invest. Ophthalmol Vis. ScL (1999) 40:2158–2162.
   Google Scholar
• D'AMATO R, LOUGHNAN M, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. ScL USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• KENYON B, BROWNE F, D'AMATO R: Effects of thalido-mide and related metabolites in a mouse model of neovascularization. Exp. Eye Res. (1997) 64:971–978.
   PubMed Web of Science ®Google Scholar
• KRUSE F, JOUSSEN A, ROHRSCHNEIDER K, BECKER M, VOLCKER H: Thalidomide inhibits corneal angiogene-sis induced by vascular endothelial growth factor. Graefes. Arch. Clin. Exp. Ophthalmol. (1998) 236:461–466.
   PubMed Web of Science ®Google Scholar
• IP M, GORIN MB: Recurrence of a choroidal neovascu-lar membrane in a patient with punctate inner choroi-dopathy treated with daily doses of thalidomide. Am. J. Ophthalmol. (1996) 122:594–5.
   PubMed Web of Science ®Google Scholar
• REICHEL E, PULIAFITO CA, DUKER JS, GUYER DR: Indocyanine green dye-enhanced diode laser photocoagulation of poorly defined subfoveal choroidal neovascularization. Ophthalmic Surg. (1994) 25:195–201.
   PubMedGoogle Scholar
• HOPE-ROSS MW, GIBSON JM, CHELL PB, CORRIDAN PG,KRITZINGER EE: Dye enhanced laser photocoagulation in the treatment of a peripapillary subretinal neovascular membrane. Acta Ophthalmol. (Copenh). (1994) 72:134–137.
   PubMed Web of Science ®Google Scholar
• MORIARTY AP: Indocyanine green enhanced diode laser photocoagulation of subretinal neovascular membranes [letter; comment]. Br. J. Ophthalmol. (1994) 78:238–239.
   PubMed Web of Science ®Google Scholar
• KUSAKA K, KISHIMOTO N, FUKUSHIMA I, OHKUMA H,UYAMA M: [An experimental study of diode laser photocoagulation and indocyanine green dye-enhanced diode laser photocoagulation in the primate retina]. Nippon Ganka Gakkai ZasshL (1994) 98:224–233.
   PubMedGoogle Scholar
• MILLER J, STINSON W, GREGORY W, EL-KOUMY H, PULIAFITO C: Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthal-mology (1991) 98:1711–1719.
   PubMed Web of Science ®Google Scholar
• KLIMAN G, PULIAFITO C, STERN D, BORIRAKCHAN-YAVAT S, GREGORY W: Phthalocyanine photodynamic therapy: new strategy for closure of choroidal neovascularization. Lasers Surg. Med. (1994) 15:2–10.
   PubMed Web of Science ®Google Scholar
• HILL RA, ESTEROWITZ T, RYAN J et al.: Photodynamic laser cyclodestruction with chloroaluminum sulfonated phthalocyanine (CASPc) or Photofrin (PII) vs. Nd:YAG laser cyclodestruction in a pigmented rabbit model. Lasers Surg. Med. (1995) 17:166–171.
   PubMed Web of Science ®Google Scholar
• ILIAKI OE, NAOUMIDI II, TSILIMBARIS MK, PALLIKARIS IG: Photothrombosis of retinal and choroidal vessels in rabbit eyes using chloroaluminum sulfonated phthalocyanine and a diode laser. Lasers Surg. Med. (1996) 19:311–323.
   PubMed Web of Science ®Google Scholar
• MILLER H, MILLER B: Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch. Ophthalmol (1993) 111:855–860.
   PubMed Web of Science ®Google Scholar
• MORI K, YONEYA S, OHTA M Et a/. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). Ophthalmology (1999) 106:1384–1391.
   Google Scholar
• HAMMER-WILSON M, GHAHRAMANLOU M, BERNS M: Photodynamic activity of lutetium-texaphyrin in a mouse tumor system. Lasers Surg. Med. (1999) 24:276–284.
   PubMed Web of Science ®Google Scholar
• HORNUNG R, HAMMER-WILSON M, KIMEL S, LIAW L, TADIR Y, BERNS M: Systemic application of photosensi-tizers in the chick chorioallantoic membrane (CAM) model: photodynamic response of CAM vessels and 5-aminolevulinic acid uptake kinetics by transplant-able tumors. J. Photochem. Photobiol (1999) 49:41–49.
   Web of Science ®Google Scholar
• PEYMAN GA, MOSHFEGHI DM, MOSHFEGHI A et a/.:Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg. Lasers. (1997) 28:409–417.
   Google Scholar
• MOSHFEGHI D, PEYMAN G, MOSHFEGHI A, KHOOBEHIB, PRIMBS G, CREAN D: Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photody-namic therapy: time dependencies. Ophthalmic Surg Lasers. (1998) 29:663–668.
   PubMedGoogle Scholar
• SCHMIDT-ERFURTH U, HASAN T, GRAGOUDAS E, MICHAUD N, FLOTTE T, BIRNGRUBER, R: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology (1994) 101:1953–61.
   PubMed Web of Science ®Google Scholar
• LIN S, LIN C, FELD J, DUKER J, PULIAFITO C: Thephotodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res. (1994) 13:513–22.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ERFURTH U, HASAN T, GRAGOUDAS E, BIRNGRUBER R: [Selective occlusion of subretinal
   Google Scholar
• KRAMER M, MILLER J, MICHAUD N et a/.:Liposomalbenzoporphyrin derivative verteporfin photody-namic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology (1996) 103:427–38.
   Google Scholar
• HAIMOVICI R, KRAMER M, MILLER JW et a/.:Localizationof lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res. (1997) 16:83–90.
   Google Scholar
• SCHMIDT-ERFURTH U, HASAN T, SCHOMACKER K, FLOTTE T, BIRNGRUBER R: In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg. Med. (1995) 17:178–88.
   PubMed Web of Science ®Google Scholar
• HUSAIN D, MILLER JW, MICHAUD N, CONNOLLY E, FLOTTE TJ, GRAGOUDAS ES: Intravenous Infusion of liposomal benzoporphyrin derivative for photody-namic therapy of experimental choroidal neovascu-larization. Arch. Ophthalmol. (1996) 114:978–985.
   PubMed Web of Science ®Google Scholar
• SCMIDT-ERFURTH U, MILLER J, SICKENBERG M et al.:Photodynamic terapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch. Clin. Exp. Ophthalmol. (1998) 236:365–374.
   PubMed Web of Science ®Google Scholar
• •A study that describes the use of Verteporfin for subfoveal CNVM, likely to be approved soon.
   Google Scholar